Cheat sheet
IC&RC ADC Cheat Sheet
Scientific Principles & Co-Occurring
- 25% of exam
- Disease Model Reward Pathway Withdrawal Signs Drug Classes Co-Occurring Conditions
Evidence-Based Screening & Assessment
- 20% of exam
- Screening Tools DSM-5-TR Criteria ASAM Dimensions Levels of Care Biopsychosocial History
Treatment, Counseling & Referral
- 30% of exam
- Motivational Interviewing Stages of Change MAT Medications Treatment Planning Discharge Planning Recovery Pathways
Professional, Ethical & Legal
- 25% of exam
- Boundaries 42 CFR Part 2 Informed Consent Client Rights Supervision
Quick Facts
- Questions 150 (125 scored, 25 pretest)
- Time Limit 3 hours
- Pass Score 500 scaled (200-800)
- Domains 4 (25/20/30/25%)
- Retake Wait 90 days minimum
- Delivery Prometric CBT or remote
- Blueprint November 2022 edition
Dependence vs Addiction SC
Physical Dependence
- Withdrawal on stopping
- Can occur with prescribed meds
Addiction
- Compulsive use despite harm
- Loss of control
- Withdrawal alone isn't addiction
Drug Classes SC
- CNS Depressants Alcohol, benzos, barbiturates
- Opioids Pain relief; overdose risk
- Stimulants Cocaine, methamphetamine
- Hallucinogens Low dependence potential
- Cannabis Low acute lethality
- Inhalants Rapid onset; organ damage
Withdrawal Signs SC
- Alcohol Withdrawal Tremor; seizures day 1-2
- Delirium Tremens Life-threatening; later onset
- Opioid Withdrawal Flu-like; not life-threatening
- Benzo Withdrawal Seizure risk like alcohol
- Stimulant Crash Fatigue, low mood, cravings
- Opioid Overdose Pinpoint pupils, slow breathing
Neurobiology & Risk Factors SC
- Disease Model Chronic brain condition
- Reward Pathway VTA to nucleus accumbens
- Tolerance Need more for effect
- Physical Dependence Withdrawal on stopping
- Cross-Tolerance Tolerance carries to similar drugs
- Top Risk Factors Trauma, family history, early use
ASAM Dimensions 1 to 6 AS
- D1→D6: Intox-Bio-Psych-Risk-Env-Person
- D1: Intoxication, withdrawal, meds D2: Biomedical conditions D3: Psychiatric, cognitive conditions D4: Substance use risks D5: Recovery environment D6: Person-centered considerations
CAGE-AID vs ASI AS
CAGE-AID
- 4-item brief screen
- 2+ yes flags risk
ASI
- 7-domain severity interview
- Guides treatment planning
- Screen vs comprehensive assessment
Level of Care Picker AS
- Mild withdrawal, stable support → Level 1 ( Outpatient )
- Moderate symptoms, some risk → Level 2 ( Intensive outpatient )
- Needs 24-hour structure → Level 3 ( Residential )
- Severe withdrawal risk → Level 3.7 ( Medically managed residential )
- Life-threatening instability → Level 4 ( Medically managed inpatient )
- Sustained remission, monitoring only → Level 1.0 ( Long-term monitoring )
Screening Tools AS
- CAGE-AID 4-item; 2+ yes flags
- ASI 7-domain severity interview
- SASSI Self-report; detects defensiveness
- ACE Adverse childhood experiences score
- AUDIT Alcohol-specific screening tool
- DAST Drug-specific screening tool
DSM-5-TR SUD Criteria AS
- Criteria Count 11 total; need 2+
- Mild 2-3 criteria
- Moderate 4-5 criteria
- Severe 6 or more criteria
- Prescribed Meds Tolerance/withdrawal don't count
ASAM Six Dimensions AS
- Dimension 1 Intoxication/withdrawal/addiction medications
- Dimension 2 Biomedical conditions
- Dimension 3 Psychiatric, cognitive conditions
- Dimension 4 Substance use-related risks
- Dimension 5 Recovery environment interactions
- Dimension 6 Person-centered considerations
ASAM Levels of Care AS
- Level 1 Outpatient care
- Level 2 Intensive outpatient
- Level 3 Residential care
- Level 4 Medically managed inpatient
- Level 0.5 Removed in 4th edition
- Decimals Mark gradation within level
Biopsychosocial History AS
- Core Areas Medical, family, employment, legal
- Collateral Sources Family, prior providers
- Testing Screens Immunoassay; fast, false positives
- Confirmatory Test GC-MS confirms positive
- Placement Goal Least restrictive, safe level
OARS Micro-Skills TR
- Open, Affirm, Reflect, Summarize
- Open-ended questions Affirmations Reflective listening Summaries
Methadone vs Buprenorphine TR
Methadone
- Full agonist
- OTP dispensing only
- QTc monitoring needed
Buprenorphine
- Partial agonist
- Ceiling effect
- Any qualified prescriber
- Full agonist vs ceiling effect
MAT Medication Picker TR
- Active opioid use, OTP access → Methadone ( Full agonist )
- Office-based opioid treatment → Buprenorphine ( Partial agonist )
- Opioid-free 7-10 days → Naltrexone ( Antagonist )
- Alcohol use disorder, adherent → Acamprosate ( Renal dosing )
- Alcohol use, needs deterrent → Disulfiram ( Aversive reaction )
- Pregnant with opioid use disorder → Methadone or buprenorphine ( Preferred over withdrawal )
Motivational Interviewing TR
- OARS Open, Affirm, Reflect, Summarize
- Change Talk Reinforce statements favoring change
- Sustain Talk Reflect; don't argue against
- Spirit Partnership, acceptance, compassion, evocation
- Ambivalence Normal; not resistance
Stages of Change Order TR
- Precontemplation -> Contemplation -> Preparation -> Action -> Maintenance
- Precontemp: not considering Contemplation: weighing pros/cons Preparation: planning to act Action: actively changing Maintenance: sustaining change
Goals vs Objectives TR
Goals
- Broad desired outcome
- Long-term direction
Objectives
- Specific measurable steps
- Time-limited and trackable
- Broad vs specific and measurable
Stages of Change TR
- Precontemplation Not considering change
- Contemplation Weighing pros and cons
- Preparation Planning to act soon
- Action Actively changing behavior
- Maintenance Sustaining the change
MAT Medication Memory Line TR
- Methadone full | Bupe partial | Naltrexone blocks
- Methadone: full agonist, OTP Buprenorphine: partial agonist, ceiling Naltrexone: antagonist, needs opioid-free
Lapse vs Relapse TR
Lapse
- Single use event
- Can be learned from
Relapse
- Return to full use pattern
- Often follows abstinence violation effect
- One slip vs full return
MAT Medications TR
- Methadone Full agonist; OTP-only
- Buprenorphine Partial agonist; ceiling effect
- X-Waiver Eliminated 2023 (CAA)
- Naltrexone Antagonist; needs opioid-free days
- Vivitrol Wait 7-10 opioid-free days minimum
- Acamprosate Renal dosing; three times daily
- Disulfiram Aversive; blocks alcohol metabolism
Domain Weight Order TR
- 25-20-30-25 percent, I to IV
- Domain I: 25% Domain II: 20% Domain III: 30% Domain IV: 25%
Treatment Planning & Process TR
- Goals Broad desired outcome
- Objectives Specific, measurable, time-limited steps
- Tuckman Stages Form, storm, norm, perform
- Relapse Triggers Emotions, conflict, social pressure
- Abstinence Violation Guilt after single lapse
- Warm Handoff Direct provider-to-provider connection
Discharge & Recovery Pathways TR
- Discharge Elements Aftercare, relapse plan, referrals
- 12-Step Mutual-aid fellowship model
- SMART Recovery Secular, CBT-based mutual aid
- Harm Reduction Reduces risk without abstinence
- Multiple Pathways No single model fits all
Consultation vs Supervision ET
Consultation
- Informal peer exchange
- Case-specific question
Supervision
- Ongoing formal oversight
- Tracks skill development
- Informal vs ongoing oversight
42 CFR Part 2 Disclosure Picker ET
- Routine treatment, payment, operations → Single TPO consent ( 2024 final rule )
- Bona fide medical emergency → Disclose without consent ( Document the emergency )
- Law enforcement has subpoena only → Still need consent ( Subpoena alone insufficient )
- Court orders Subpart E hearing → Disclosure permitted ( Good-cause hearing required )
- Subcontractor needs client data → QSOA required ( Qualified service agreement )
- Suspected child abuse, initial report → State law applies ( Initial report exception )
Boundaries & Self-Disclosure ET
- Dual Relationship Another role with client
- Self-Disclosure Rule Serves client; stays brief
- Scope of Practice Set by training, credential
- Conflict of Interest Disclose; step back
Court Order vs Subpoena ET
Court Order
- Subpart E hearing required
- Permits Part 2 disclosure
Subpoena Alone
- Not sufficient alone
- No disclosure without order
- Order compels; subpoena doesn't
42 CFR Part 2 ET
- 2026 Compliance Required by Feb 16 2026
- Single TPO Consent Covers treatment, payment, operations
- SUD Notes Still need separate consent
- Court Order Subpart E hearing; not subpoena
- QSOA Qualified service organization agreement
- Medical Emergency Bona fide exception; no consent
Informed Consent & Rights ET
- Informed Consent Purpose, risks, benefits, alternatives
- Voluntary No coercion; can withdraw
- Client Rights Dignity, refuse care, grievance
- Grievance Process No retaliation; documented response
Supervision & Documentation ET
- Supervision Ongoing oversight of casework
- Consultation Informal case discussion
- Documentation Standard Objective, timely, specific
- Record Security Limited access; written policy
- Cultural Humility Ongoing self-reflection; not checklist
Common Traps
Tolerance ≠ Addiction
- Tolerance is pharmacological need ≠ Addiction adds compulsive harmful use
Lapse ≠ Relapse
- Lapse is one slip ≠ Relapse is sustained return
Consultation ≠ Supervision
- Consultation is informal peer input ≠ Supervision is ongoing formal oversight
Subpoena ≠ Court Order
- Subpoena alone is insufficient ≠ Court order needs Subpart E hearing
CAGE-AID ≠ Diagnosis
- CAGE-AID only screens risk ≠ DSM-5-TR criteria give diagnosis
Readiness ≠ Standalone Dimension
- 4th edition assesses readiness everywhere ≠ Dimension 4 now substance use risks
Methadone ≠ Buprenorphine
- Methadone is full agonist ≠ Buprenorphine is partial with ceiling
Last Minute
- 1. Weights: 25-20-30-25 percent
- 2. 150 questions; 125 scored only
- 3. Pass is 500 scaled score
- 4. 90-day minimum wait to retake
- 5. 4 failed attempts trigger remediation
- 6. ASAM 4th edition: six dimensions
- 7. Part 2 compliance due Feb 2026
- 8. Single consent now covers TPO
- 9. Naltrexone needs 7-10 opioid-free days
- 10. Buprenorphine needs no federal X-waiver
- 11. OARS = core MI skills
- 12. DSM-5-TR severe means 6+ criteria
IC&RC Alcohol & Drug Counselor (ADC) Examination
- Practice Questions 165 questions Study Guide 56 topics Cheat Sheet 93 facts Flashcards 50 cards Free CE Podcast